AzTrials
AzTrials

Parkinson DiseaseNS-PARKNCT04888364

French Parkinson's Disease Cohort - NS-PARK

An observational study of Parkinson Disease, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Read more about this study

Who is it for?
Ages 10 years and olderHealthy volunteers can take part
Conditions the study is for
Parkinson Disease
How many people
30,000 participants
Where
1 siteFrance
Study dates
16 Jun 2021to 31 Dec 2034
How long will I take part?
15 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 10 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: All patients followed at one expert center for PD or associated centers in France.

Who may be able to join

  • Diagnosis of Parkinson's disease according to UK PD brain bak criteria
  • OR diagnosis of parkinsonian syndrome: multiple system atrophy, progressive supranuclear palsy, dementia with Lewy body, or corticobasal syndrom
  • OR Subjects at risk of PD defined as :
  • No symptom or diagnosis of Parkinson's disease nor parkinsonian syndrome, and relative to a patient with a diagosis of PD or parkinsonian syndrome, or carrier of a known mutation responsible for a genetic form of PD or patient with a diagnosis of idiopathic REEM sleep disorder or prodromal form of PD as defined by MDS criteria (Berg et al., 2015)
  • AND for all participants
  • Affiliated to social security
  • Age > 10 years

Who cannot join

  • Subject under legal protection
  • Subject who do not consent to the research
  • for the optional skin biopsy only: clinically significant coagulation abnormalities or anticoagulant treatment

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Jean Christophe MD CORVOL, PU-PH contact

33 1 42 16 57 66

jean-christophe.corvol@aphp.fr

France1 site, 1 recruiting

  • Centre 01 Paris

    Paris, 75013

    Jean Christophe MD Corvol, Pr, 33 1 42 16 57 66, jean-christophe.corvol@aphp.fr

    Jean Christophe MD Corvol, Pr

    Recruiting

Other trials in France

About this study

Official title: Cohort of the French Clinical Research Network for Parkinson's Disease (NS-PARK Cohort)

The aim of NS-PARK cohort are to describe the natural history of Parkinson's disease (PD), and to propose patients stratification models based on PD pathophysiological mechanisms. Patients are included at all PD expert centers in France. Standardized demographic, diagnosis, motor and non-motor symptoms evaluation, and treatment information are collected, and clinical data are updated at each visit of the patient at the center. A blood sampling is perform at baseline for genetic testing and implement an associated biocollection.

Read the detailed description

The national clinical research network for Parkinson's disease (NS-PARK/FCRIN) reassembles all expert centers in Parkinson's disease (PD) in France. Its aim is to promote clinical research in Parkinson's disease and movement disorder, to better understand the pathophysiology of PD, foster the development of new therapeutic strategies, and move towards personalized medicine. To help centers for prescreening, a national registry of PD patients followed in each centers has been implemented in 2016 to collect minimal relevant clinical information of patients followed in each center including demographic data, age at diagnosis, standardized motor and non-motor symptoms evaluation, and treatment. Data are updated at each visit of the patient in the center. De facto, this registry became a longitudinal cohort of PD patients followed in NS-PARK centers. In 2020, NS-PARK received funding to associate a biocollection to this clinical cohort.

The aim of NS-PARK cohort are to describe the natural history of PD progression in clinical routine in France, to develop new models of PD describing the different progression profiles, and to propose patients stratification based on PD pathophysiological mechanisms. The cohort will also serve as a platform to discover new PD genes and genetic modifiers of disease progression or response to treatment.

Keywords
Parkinson's disease, Genetics
Medical subject headings
Parkinson Disease

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Disease progression

    Hoehn and Yahr score change

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  2. Motor and non-motor complications

    Occurence of motor (dyskinesia or motor fluctuations) or non-motor (dementia, dysautonomia, behavioral or psychiatric disorders, sleep disorders, falls, ...) complication

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  3. Modification of antiparkinsonian treatment doses

    Modification of antiparkinsonian treatment during follow-up will be measured as levodopa equivalent daily doses

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

Secondary outcomes (6)

  1. Predictive factorsof PD progression: motor or non motor symptoms

    Motor or non motor symptoms as measured by MDS-UPDRS scores will be used as predictive factors for primary outcomes

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  2. Predictive factors of PD progression: genetic variants

    Genetic variants in PD genes or the Genetic PD risk score will be used as predictive factors for primary outcomes.

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  3. Predictive factors of PD progression: brain imaging markers

    Brain imaging makers (iron or neuromelanine content of the substantia nigra) will be used as predictive factors for primary outcomes

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  4. Clusters of patients with similar disease progression profiles

    Clustering analyses will be performed on disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) to identify homogeneous groups of patients (clusters) sharing similar disease progression profiles.

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  5. Clusters of patients with similar genetic and disease progression profiles

    Co-clustering analysis of disease progression markers (Hoehn and Yahr score, MDS-UPDRS scores, and doses of treatment (levodopa equivalent daily doses)) and genetic markers (variants in PD genes or the Genetic PD risk score).

    Measured: through the end of follow-up in the cohort, at least 2 years, and average of 5 years

  6. Genetic mutations associated with familal forms of PD

    Genetic mutations will be screened by different methods (gene panels, whole exome or whole genome) in familial forms of PD. Mutations co-segregated with PD will be considered as potentially associated with the disease.

    Measured: through study completion, 15 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2021
  2. Study start16 Jun 2021
  3. Primary completion31 Dec 2032 (estimated)
  4. Study completion31 Dec 2034 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
30,000 participants (estimated)
Target duration
15 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT04888364
Sponsor's protocol ID
C16-56
Other IDs
2019-A01929-48
Acronym
NS-PARK
Status last verified
Aug 2026
First submitted
19 Apr 2021
Last updated
20 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Lanore A, Januel E, Bertille N, Fabbri M, Mariani LL, Mangone G, Sambin S, Menon PJ, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Dupont G, Moro E, Defebvre L, Houeto JL, Thobois S, Azulay JP, Geny C, Frismand S, Damier P, Giordana C, Castelnovo G, Ansquer S, De Maindreville AD, Drapier S, Maltete D, Tranchant C, Rascol O, Tubach F, De Rycke Y, Corvol JC; French NS-Park Network. Motor and Non-motor Complications Following Different Early Therapies in Parkinson's Disease: Longitudinal Analysis of Real-Life Clinical and Therapeutic Data from the French NS-PARK Cohort. CNS Drugs. 2025 Sep;39(9):879-891. doi: 10.1007/s40263-025-01193-5. Epub 2025 May 25.

    PubMed 40415148

Questions about this trial

What is this clinical trial studying?

An observational study of Parkinson Disease, run by Institut National de la Santé Et de la Recherche Médicale, France at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 7 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 20 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Jean Christophe MD CORVOL, PU-PH (33 1 42 16 57 66, jean-christophe.corvol@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Disease progression (time frame: through the end of follow-up in the cohort, at least 2 years, and average of 5 years). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04888364, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Aug 2026; AzTrials last refreshed its copy on 26 Oct 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in